Three Years Undetectable, and Still Hesitant to Ask
A 68-year-old, three years past a prostatectomy for low-risk prostate cancer, with an undetectable PSA and hypogonadal symptoms he almost didn't mention — testing how far a decades-old contraindication has actually moved.
Walter S. spent thirty-eight years as a high school shop teacher before retiring, and still keeps a woodworking bench in his garage where he builds furniture for each of his six grandchildren in turn. He was diagnosed with Gleason 6 prostate cancer during a routine screening PSA three years ago, treated with radical prostatectomy, and has had an undetectable PSA at every follow-up since. He almost didn't mention the fatigue and low libido that had crept in over the past year, assuming a prostate cancer survivor simply doesn't get to raise testosterone as a topic — a belief his primary care physician had to actively talk him out of before ordering the labs at all.
His testosterone came back at 224 ng/dL on two confirmed morning draws, genuinely low, alongside symptoms consistent with the diagnosis rather than simply age. The reflexive teaching for decades — going back to Huggins and Hodges' 1941 work establishing that androgen deprivation controls advanced prostate cancer — has been that any testosterone exposure feeds prostate cancer growth in direct proportion to the dose, making replacement categorically contraindicated in any man with a personal history of the disease, treated or not. The saturation model, developed over the past two decades, offers a genuinely different reading of the same underlying biology: prostatic androgen receptors saturate at a relatively low serum testosterone level, well below the normal physiologic range, meaning that once a threshold is crossed, additional testosterone produces no further increase in androgen-driven receptor activation. That model predicts, and a growing body of outcome data has since supported, that raising a hypogonadal man's testosterone from a deficient level back into the normal range behaves differently than the castrate-to-supraphysiologic range Huggins actually studied.
A propensity-matched study following twenty-four hypogonadal men on testosterone after prostate cancer treatment against seventy-two matched men without it found no significant difference in treatment-free survival over a median follow-up of nearly six years — reassuring, though a study of this size can rule out a large effect, not a small one. Real-world prescribing has moved with the evidence: surveys of practicing urologists describe a shift from roughly three in three hundred willing to consider testosterone in a prostate cancer survivor two decades ago to the substantial majority today, though the shift in stated willingness has outpaced the volume and duration of the outcome data actually available to support it.
Survivorship clinic, testing a decades-old rule against modern data
The reflexive contraindication comes from Huggins' work on castration versus supraphysiologic androgen exposure in advanced, untreated disease — a completely different biological situation from a hypogonadal man three years past a prostatectomy with an undetectable PSA. The saturation model explains why: prostatic androgen receptors saturate at a low serum level, so raising him from deficient back to normal shouldn't drive growth the way the old model assumed, because there's no residual gland left to grow in the first place.
I'm not defending the old blanket rule, and I agree the mechanism argument is sound. What I'm not willing to treat as settled is that the outcome data behind it is deep enough yet — the reassuring studies are mostly small, retrospective, and don't run past five or six years of follow-up. A recurrence in a man already on testosterone is genuinely harder to interpret and manage than one caught off it, and that asymmetry deserves more than a mechanism argument to override.
Prescribing willingness among urologists really has shifted from a handful in hundreds to a clear majority over twenty years — but a shift in what colleagues are comfortable doing isn't the same claim as a shift in how much outcome data actually backs it, and I don't want us to quietly substitute one for the other.
Nobody here is actually arguing against treating him — the disagreement is about how tightly to watch afterward. A concrete plan settles that without either of you having to fully concede the point: PSA and testosterone rechecked at three months instead of his usual annual interval, with his oncologist looped in explicitly rather than this staying a primary care and endocrinology decision alone. That gives the caution real teeth without withholding treatment from a man whose own numbers, and his surgery, both argue for it.
Agreed: testosterone gel started today, with PSA and testosterone rechecked at three months rather than his standard annual survivorship interval, and his treating oncologist added explicitly to the follow-up loop rather than left to learn about it at the next scheduled visit.
Not agreed, and left on record rather than smoothed over: the urologist's underlying concern that the reassuring outcome literature, while real, hasn't yet accumulated the follow-up depth to fully retire the caution built into the older contraindication. The accelerated monitoring plan was accepted by all three voices as the right response to that open question, not as proof it has been resolved.